Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reissue Patent
2007-06-26
2007-06-26
Dentz, Bernard (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S283000, C544S361000, C546S014000, C546S041000, C546S048000
Reissue Patent
active
10346835
ABSTRACT:
(20S) esters of camptothecin analogs are provided. The compounds are (20S) esters of an oxyalkanoic acid and camptothecin, whichdelete-start id="DEL-S-00001" date="20070626" ?isdelete-end id="DEL-S-00001" ?insert-start id="INS-S-00001" date="20070626" ?areinsert-end id="INS-S-00001" ?optionally substituted at the 7, 9, 10, 11, and 12 positions of the camptothecin ring. The compounds are useful for treating cancer.
REFERENCES:
patent: 4399282 (1983-08-01), Miyasaka et al.
patent: 4943579 (1990-07-01), Vishnuvajjala et al.
patent: 5916896 (1999-06-01), Wall et al.
patent: 5965566 (1999-10-01), Greenwald et al.
patent: 6028078 (2000-02-01), Hausheer et al.
patent: 6040313 (2000-03-01), Wall et al.
patent: 6057303 (2000-05-01), Haridas et al.
patent: 6096336 (2000-08-01), Cao et al.
patent: 6113906 (2000-09-01), Greenwald et al.
patent: 6114529 (2000-09-01), Kawaguchi et al.
patent: 6120793 (2000-09-01), Cao et al.
patent: 6127355 (2000-10-01), Greenwald et al.
patent: 6153655 (2000-11-01), Martinez et al.
patent: 6207832 (2001-03-01), Curran et al.
patent: 6339091 (2002-01-01), Bigg et al.
patent: 6350756 (2002-02-01), Yang et al.
patent: 6403604 (2002-06-01), Yang et al.
patent: 0 861 842 (1998-09-01), None
patent: WO 95/10304 (1995-04-01), None
patent: WO 96/26950 (1996-09-01), None
patent: WO 97/19085 (1997-05-01), None
patent: WO 97/28165 (1997-08-01), None
patent: WO 98/13059 (1998-04-01), None
patent: WO 98/14459 (1998-04-01), None
patent: WO 98/28304 (1998-07-01), None
patent: WO 98/35940 (1998-08-01), None
patent: WO 98/51703 (1998-11-01), None
patent: WO 99/17805 (1999-04-01), None
patent: WO 00/66127 (2000-11-01), None
patent: WO 00/67801 (2000-11-01), None
patent: WO 03/014069 (2003-02-01), None
Bom, David et al., “The Novel Silatecan 7-tert-Butyldimethylsilyl-10-hydroxycamptothecin Displays High Lipophilicity, Improved Human Blood Stability, and Potent Anticancer Activity,” J. Med. Chem., 2000 v. 43, pp. 3970-3980.
Cao, Zhisong et al., “Alkyl Esters of Camptothecin of Camptothecin and 9-Nitrocamptothecin: Synthesis in Vitro Pharmacokinetics, Toxicity, and Antitumor Activity,” J. Med. Chem., 1998, v. 41, pp. 31-37.
Dallavalle, Sabrina et al., “Novel 7-Substituted Camptothecins with Potent Antitumor Activity,” J. Med. Chem., 2000, v. 43, pp. 3963-3969.
Del Poeta, Maurizio et al., “Comparison of In Vitro Activities of Camptothecin and Nitidine Derivatives against Fungal and Cancer Cells,” Antimicrobial Agents and Chemotherapy, Dec. 1999, v. 43, n. 12, pp. 2862-2868.
Kingsbury, William D. et al., “Synthesis of Water-Soluble (Aminoalkyl)camptothecin Analogues: Inhibition of Topoisomerase I and Antitumor Activity,” J. Med. Chem., 1991, v. 34, pp. 98-107.
O'Leary, J. et al., “Camptothecins: a Review of their Development and Schedules of Administration,” European Journal of Cancer, 1998, v. 34, n. 10, pp. 1500-1508.
Sawada, Seigo et al., “Chemical Modification of an Antitumor Alkaloid Camptothecin: Synthesis and Antitumor Activity of 7-C-Substituted Camptothecins,” Chem. Pharm. Bull., 1991, v. 39, n. 10, pp. 2574-2580.
Sawada, Seigo et al., “Synthesis and Antitumor Activity of 20(S)-Camptothecin Derivatives: Carbamate-Linked, Water-Soluble Derivatives of 7-Ethyl-10-hydroxycamptothecin,” Chem. Pharm. Bull., 1991, vo. 39, n. 6, pp. 1446-1454.
Takayama, Hiromitsu et al., “Synthesis of a New Class of Camptothecin Derivatives, the Long-Chain Fatty Acid Esters Of 10-Hydroxycamptothecin, as a Potent Prodrug Candidate, and their In Vitro Metaboli Conversion by Carboxylesterases,” Bioorganic & Medicinal Chemistry Letters 8, 1998, pp. 415-418.
Wall, Monroe E. et al., “Camptothecin and Taxol: Discovery to Clinic-Thirteenth Bruce F. Cain Memorial Award Lecture,” Cancer Research 55, Feb. 15, 1995, pp. 753-760.
Wall, Monroe E. et al., “Plant Antitumor Agents. 301a,bSynthesis and Structure Activity of Novel Camptothecin Analogs,” J. Med. Chem., 1993, v. 36, pp. 2689-2700.
Zhao, Rulin et al., “Synthesis, topoisomerase I inhibitory activity and in vitro cytotoxicity of camptothecin derivatives bearing five-membered heterocycle containing 10-substituents,” Anti-Cancer Drug Design, 1998, v. 13, pp. 145-147.
Bomgaars, et al., “The Development of Camptothecin Analogs in Childhood Cancers,” Oncologist 6:506-516 (2001).
Garcia-Carbonero et al., “Current Perspectives on the Clinical Experience, Pharmacology and Continued Development of the Camptothecins”,Clinical Cancer Research, Mar. 2002, vol. 8, 641-661.
Keskin, et al., “Characterization of anticancer agents by their growth inhibitory activity and relationships to mechanism of action and structrure”, Anti Cancer Drug Design, 15:2:78-98 (2000).
Lerchen, “Milestones in Camptothecin Research,” Drugs of the Future 27:869-876 (2002).
Maliepaard et al., “Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BRCP inhibitor GF120918,”Clinical Cancer Research7:935-941, 2001.
Nomoto et al., “Characterization of a human small-cell lung cancer cell line resistant to a new water-soluble camptothecin derivative, DX-8951f,”Jpn. J. Cancer Res.89:1179-1186, 1998.
Perego et al., “A Novel 7-modified Camptothecin Analog Overcomes Breast Cancer Resistance Protein-associated Resistance in a Mitoxantrone-selected Colon Carcinoma Cell Line”,Cancer Research, Aug. 15, 2001, 61, 6034-6037.
Pollack et al., “Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo,” Cancer Research 59:4898-4905, 1999.
Saltz L. et al., “CPT-11 (Irinotecan) and 5-Fluorouacil: a Promising Combination for Therapy of Colorectal Cancer”, European Journal of Cancer, 1996, vol. 32A, No. Suppl. 3, pp. 524-531.
Shabat D et al., “Multiple event activation of a generic prodrug trigger by antibody catalysis”, Proceedings of the National Academy of Sciences of USA, 96:6925-6930, Jun. 1999.
Singer et al., “Conjugation of Camptothecins to Poly-(L-Glutamic Acid)”, Annals of the New York Academy of Sciences, 2000, vol. 922, pp. 136-150.
XP 002033248, ASTRACT, WPI, vol. 46, No. 89.
XP 002033250, ABSTRACT, WPI, vol. 45, No. 89.
Saltz et al., CPT-11 (Irinotecan) and 5-Fluorouracil: a Promising Combination for Therapy of Colorectal Cancer, European Journal of Cancer, 32A:Supp 3::S24-S31 (1996).
Singer et al., Conjugation of Camptothecins to Poly-(L-Glutamic Acid)), Annals of the New York Academy of Sciences, 922:136-150 (2000).
Abstract No. XP002033248 WPI Derwent vol. 46, No. 89 (1989).
Abstract No. XP002033250 WPI Derwent vol. 45, No. 89 (1989).
Keskin et al., Characterization of anticancer agents by their growth inhibitory activity and relationships to mechanism of action and structure, Anti-Cancer Drug Design , 15:79-98 (2000).
Pan Xiando
Wang Huijan
Yang Li-Xi
California Pacific Medical Center
Catholic Healthcare West
Dentz Bernard
Foley & Lardner LLP
LandOfFree
Camptothecin derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Camptothecin derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Camptothecin derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3823083